Trending NewsTrending NewsNYSE:JNJ Johnson & Johnson (JNJ) Stock Price, News & Analysis $260.44 +5.66 (+2.22%) As of 11:36 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Johnson & Johnson Stock (NYSE:JNJ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Johnson & Johnson alerts:Sign Up Key Stats Today's Range$255.73▼$260.2250-Day Range$252.90▼$278.6652-Week Range$184.66▼$281.07Volume1.25 million shsAverage Volume7.96 million shsMarket Capitalization$627.62 billionP/E Ratio30.14Dividend Yield2.06%Price Target$276.22Consensus RatingModerate Buy Company Overview Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world. The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension. The MedTech segment develops technologies and products used in surgery, orthopaedics, cardiovascular care, vision care and other medical specialties. Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson has a long history in healthcare and formerly operated a substantial consumer health business. That consumer health business was separated into Kenvue in 2023, allowing Johnson & Johnson to focus primarily on pharmaceutical and medical technology operations. The company is led by Chairman and Chief Executive Officer Joaquin Duato.AI Generated. May Contain Errors. Read More Johnson & Johnson Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreJNJ MarketRank™: Johnson & Johnson scored higher than 95% of companies evaluated by MarketBeat, and ranked 15th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingModerate Buy Consensus RatingJohnson & Johnson has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 18 buy ratings, 6 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Johnson & Johnson is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageJohnson & Johnson has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Johnson & Johnson's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth9.53% Earnings GrowthEarnings for Johnson & Johnson are expected to grow by 9.53% in the coming year, from $11.54 to $12.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Johnson & Johnson is 29.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Johnson & Johnson is 29.53, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.95.Price to Earnings Growth RatioJohnson & Johnson has a PEG Ratio of 2.48. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioJohnson & Johnson has a P/B Ratio of 7.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Johnson & Johnson's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.88% of the float of Johnson & Johnson has been sold short.Short Interest Ratio / Days to CoverJohnson & Johnson has a short interest ratio ("days to cover") of 3.65, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Johnson & Johnson has recently decreased by 2.22%, indicating that investor sentiment is improving. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldJohnson & Johnson pays a meaningful dividend of 2.09%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthJohnson & Johnson has been increasing its dividend for 64 years.Dividend CoverageThe dividend payout ratio of Johnson & Johnson is 62.11%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 42.41% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.Read more about Johnson & Johnson's dividend. News and Social Media3.5 / 5News Sentiment0.64 News SentimentJohnson & Johnson has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 51 news articles for Johnson & Johnson this week, compared to 9 articles on an average week.Search InterestOnly 70 people have searched for JNJ on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows67 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is an increase of 109% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Johnson & Johnson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,064,544.00 in company stock.Percentage Held by Insiders0.16% of the stock of Johnson & Johnson is held by insiders.Percentage Held by Institutions69.55% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Johnson & Johnson's insider trading history. Receive JNJ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JNJ Stock News Headlines24/7 Market News Highlights NeOnc, Revolution Medicines, Moderna, Merck, Johnson & Johnson and Genmab, AbbVie in 2026 Cancer Treatment Advances1 hour ago | quiverquant.comQJohnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?2 hours ago | 247wallst.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 7 at 1:00 AM | Altimetry (Ad)Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?2 hours ago | 247wallst.com3 Healthcare Dividend Stocks Offering More Than Just IncomeAbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.September 30, 2026 | marketbeat.comThe September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks (JNJ)As Fed and inflation worries mount, Casey's General Stores, Johnson & Johnson, and PepsiCo stand out as defensive dividend payers with healthy balance sheets, growing payouts, and buyback programs.September 17, 2026 | marketbeat.comThe September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks (JNJ)As Fed and inflation worries mount, Casey's General Stores, Johnson & Johnson, and PepsiCo stand out as defensive dividend payers with healthy balance sheets, growing payouts, and buyback programs.September 17, 2026 | marketbeat.com3 Healthcare Stocks for 3 Stages of Life (JNJ)Healthcare stocks Eli Lilly, UnitedHealth Group, and Johnson & Johnson offer options for investors of different ages, combining growth potential, turnaround momentum, and reliable dividends.September 15, 2026 | marketbeat.comSee More Headlines JNJ Stock Analysis - Frequently Asked Questions How have JNJ shares performed this year? Johnson & Johnson's stock was trading at $207.07 at the start of the year. Since then, JNJ shares have increased by 23.1% and is now trading at $254.8530. How were Johnson & Johnson's earnings last quarter? Johnson & Johnson (NYSE:JNJ) posted its earnings results on Wednesday, July, 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.06. The firm's revenue was up 6.6% compared to the same quarter last year. Read the conference call transcript. Does Johnson & Johnson have any subsidiaries? The following companies are subsidiaries of Johnson & Johnson: Momenta Pharmaceuticals, TARIS Biomedical, Verb Surgical, Auris Health, Ci:z Holdings, Zarbee's Naturals, Orthotaxy, and more. Who are Johnson & Johnson's major shareholders? Johnson & Johnson's top institutional investors include Ferguson Wellman Capital Management Inc. (0.03%), Eastern Bank (0.01%), MassMutual Private Wealth & Trust FSB (0.01%) and Neville Rodie & Shaw Inc. (0.01%). Insiders that own company stock include & Johnson Johnson, Jennifer L Taubert, Kathryn E Wengel, Timothy Schmid, Vanessa Broadhurst, Robert J Decker, Elizabeth Forminard and Mark A Weinberger. View institutional ownership trends. How do I buy shares of Johnson & Johnson? Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Johnson & Johnson own? Based on aggregate information from My MarketBeat watchlists, some other companies that Johnson & Johnson investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), UnitedHealth Group (UNH), Gilead Sciences (GILD), Corning (GLW), NextEra Energy (NEE) and Devon Energy (DVN). Company Calendar Last Earnings7/15/2026Record date for 9/8 Dividend8/25/2026Ex-Dividend for 9/8 Dividend8/25/2026Dividend Payable9/08/2026Today10/07/2026Next Earnings (Estimated)10/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 2 days ago, JNJ's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:JNJ CIK200406 Webwww.jnj.com Phone(732) 524-0400Fax732-214-0332Employees138,200Year Founded1886Price Target and Rating Average Price Target for Johnson & Johnson$276.22 High Price Target$320.00 Low Price Target$210.00 Potential Upside/Downside+6.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)$8.63 Trailing P/E Ratio30.09 Forward P/E Ratio22.50 P/E Growth2.48Net Income$26.80 billion Net Margins21.48% Pretax Margin25.73% Return on Equity32.42% Return on Assets13.35% Debt Debt-to-Equity Ratio0.44 Current Ratio1.09 Quick Ratio0.81 Sales & Book Value Annual Sales$97.93 billion Price / Sales6.39 Cash Flow$14.50 per share Price / Cash Flow17.91 Book Value$33.85 per share Price / Book7.67Miscellaneous Outstanding Shares2,409,898,000Free Float2,406,042,000Market Cap$625.71 billion OptionableOptionable Beta0.21 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSE:JNJ) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersWashington Is Broke—Could YOUR Savings Be Next?The Department of Justice recently argued in court that cash is not legally property, raising new questions fo...Priority Gold | SponsoredFDA Clears This Under-$5 Biotech for Phase 2 Clinical TrialA NASDAQ-listed biotech just cleared a major regulatory milestone. The FDA has cleared its lead multiple scler...The Tomorrow Investor | Sponsored25 candidates screened. 5 made it.More than 25 candidates were screened for share price between $1 and $5, market cap above $100 million, daily ...TradingTips | SponsoredNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | SponsoredParisian Penthouse: $650 a month (and your own chauffeur)A penthouse apartment for 650 a month in one of the ritziest neighborhoods in the city, comparable to Manhatta...International Living | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredTomorrow morning's stock alertOur research analysts are set to release their next stock idea tomorrow morning just before 12:00 PM Eastern. ...The Early Bird | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Johnson & Johnson Please log in to your account or sign up in order to add this asset to your watchlist. Share Johnson & Johnson With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
